Breakthrough treatment with the first intelligent balloon catheter for cardiac arrest: Now CE marked
Saving hearts and minds
Neurescue develops cardiovascular devices to improve outcomes for emergency patients. Our flagship product, the NEURESCUE device, an intelligent & fluoroscopy-free balloon catheter, is the first approved for the treatment of non-shockable cardiac arrest. By increasing blood flow to the brain and heart, the NEURESCUE device helps increase resuscitation rates.
Aortic balloon occlusion
1.
The NEURESCUE device is used to inflate a balloon in the descending aorta through a femoral artery introducer sheath. It is the world’s first balloon catheter approved for non-shockable cardiac arrest treatment.
2.
Non-shockable cardiac arrest cannot be treated with defibrillators. Aortic balloon occlusion is a technique that supercharges blood flow to the brain & heart within one minute from deployment, thereby increasing resuscitation rates.
3.
Increasing blood flow to the brain and the heart can achieve a return of spontaneous circulation (a regained heartbeat) or conversion to a shockable rhythm, either of which bridges the patient to additional therapy.
The NEURESCUE device is designed to increase blood flow to the brain and heart and enable life-saving treatment. The company has been awarded several innovation grants by the European Commission.
Only 1 out of 20 survive a non-shockable cardiac arrest today.
Current standard of care does not reach high enough blood flow to resuscitate most patients. Neither does it buy enough time for more advanced treatment of the patient, such as heart-lung machine. Neurescue seeks to address this unmet need with next-generation medical technology.
20%
Cardiac arrest is a major health problem accounting for an estimated 20% of all premature deaths.
81%
81% of all cardiac arrest patients present as non-shockable, making them ineligible for defibrillation, and only 4% survive a non-shockable cardiac arrest today.
35%
Today's CPR only replaces 35% of blood flow, which is not enough to resuscitate most patients; and does not buy enough time to bridge patients to advanced treatments.
Our solution
The NEURESCUE device is the first computer-aided aortic balloon catheter with intelligent safety feedback & pressure-controlled inflation. This allows physicians to insert and inflate a balloon during cardiac arrest, which redirects blood flow to the heart & brain, where it is needed the most, to:
1) achieve immediate resuscitation from cardiac arrest.
2) bridge more patients to treatments such as ECMO, heart pumps, stents, pacemakers and more.
It is the first device specifically approved for non-shockable cardiac arrest. An estimated 81% of all cardiac arrest patients present as non-shockable, making them ineligible for defibrillation. Today, only 4% of these patients survive (PMID: 33248155).
The NEURESCUE device directly addresses this urgent unmet need. With its Class III CE Mark, the device is the first-of-its-kind available for non-shockable cardiac arrest treatment.
Want to know more?
Don't hesitate to get in touch.
This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 811866
DK OFFICE
Antonigade 11, 2nd floor,
1106, Copenhagen
UK OFFICE
45 Albemarle Street, 3rd floor,
Mayfair, W1S 4JL, London
Saving hearts and minds